Total
USD $0.00
 
Bulgaria

Company Overview of Sopharma AD (Софарма АД)

An EMIS Company Report EMIS is an ISI Emerging Markets Group Company Company Description

Bulgarian drug maker Sopharma, which was established in 1933, is active in development, manufacturing and marketing of over 200 human pharmaceutical products.
The company produces mostly cardiovascular drugs, analgesics and vitamins and exports its output to more than 10 countries, with top destinations being Russia and other ex-Soviet states.
In July 2000, local company Elpharma set up by the engineering and trading firm Elektroimpex and Unifarm, a small local pharmaceuticals company, bought a 66.94% stake in Sopharma for USD 24 million. Elpharma also pledged to invest USD 7.5 million in Sopharma over the next three years. In mid-2003, Sopharma launched a consolidation of its subsidiaries in Bulgaria by merging with local drug maker Vramed.
The following year, the Sofia-based firm acquired control of local debt-ridden pharmaceuticals and rose oil producer Balgarska Rosa Sevtopolis.
In January 2006, U.S. Gramercy Emerging Market Fund bought a 7.57% stake of Sopharma from its majority owner for EUR 19.7 million. The U.S. investment fund gradually raised its stake in the drug maker to 17% by December 2006.
In December 2006, Sopharma bought for an undisclosed sum a 70% stake of local firm MineralCommers - the only manufacturer of amorphous silica in the Balkans.
In October 2007 Sopharma bought 108,500 shares, or less than 1.0 pct, from the IPO of Latvian peer Olainfarm in a bid to expand its presence on the Baltic market. The acquisition was part of the company’s plans to list on the Warsaw bourse by February 2008 and thus become the first Bulgarian firm to be listed on two stock exchanges. Also in October, Sopharma also bought 4.72% in Momina Krepost, raising its stake in the disposable medical supplies maker to 42.26%.
In November 2007, the blue-chip drug maker bought some 74% in Ukranian pharmaceutical producer Vitamini for an undisclosed sum.
In March 2008, Sopharma received approval from the Serbian anti-trust body to take control of Belgrade-based pharmaceutical firm Ivancic and Sons for an undisclosed sum.
In December 2009, Sopharma acquired a 51% stake in Latvian pharmaceutical wholesaler Briz at the amount of EUR 2.25 million.
The Sopharma group operates 14 pharmaceutical plants in Bulgaria, one in Ukraine and two in Serbia as of end-2012.

Need a report on this company? USD 29.95 Industry: Medicinal and Botanical Manufacturing Available in: English & Bulgarian Format: PDF Download Most recent financial data: 2017 Buy full report

Report contents

On purchasing the report for this company you will have access to a PDF containg the most recent data for Sopharma AD from the EMIS database.

To give you a clear idea of the information provided, you can download a sample report for a different company below.

Download a sample report
NAICS Industry Classification
Main Activities: Medicinal and Botanical Manufacturing | Pharmaceutical Preparation Manufacturing
Contact Information

Headquarters
16 Iliensko Shose Str.
Sofia; Sofia - city; Postal Code: 1220

Tel: +359-2-813-, +359-2-813-, +359-2-813-
Fax: +359-2-936-, +359-2-936-

Email:
@sopharma.bg

Website:
http://www.sopharma.bg/

Basic Information
Total Employees:
1,921 (2017)
Outstanding Shares:
Provided in the purchased report
Registered Capital:
Provided in the purchased report
Financial Auditors:
Provided in the purchased report
Incorporation Date:
November 15, 1991
Key Executives
Provided in the purchased report
Executive Director and Member of the Board of Directors
Provided in the purchased report
Member of the Board of Directors
Provided in the purchased report
Member of the Board of Directors
Provided in the purchased report
Member of the Board of Directors
Provided in the purchased report
Member of the Board of Directors
More
Ownership Details
Donev Investments Holding AD
25.2%
Telecomplect Invest AD
20.41%
Rompharm Company OOD
7.52%
ZUPF Aliants Balgariya Pensionen fond
4.99%
Subsidiaries
Elektronkomers EOOD
100%
Sopharma Kazahstan EOOD (Kazakhstan)
100%
Sopharma Ukraine (Ukraine)
100%
More
M&A deals (Not included in report)

Report contents

On purchasing the report for this company you will have access to a PDF containg the most recent data for Sopharma AD from the EMIS database.

To give you a clear idea of the information provided, you can download a sample report for a different company below.

Download a sample report
Key Financial Highlights
Annual growth percentages* for latest two years in USD terms. Absolute financial data is included in the purchased report.
Net sales revenue
33.25%
Total operating revenue
33.2%
Operating profit (EBIT)
-14.91%
EBITDA
-3.95%
Net Profit (Loss) for the Period
-17.74%
Total assets
11.68%
Total equity
3.02%
Operating Profit Margin (ROS)
-2.68%
Net Profit Margin
-2.42%
Return on Equity (ROE)
-1.54%
Debt to Equity Ratio
7.86%
Quick Ratio
-18.53%
Cash Ratio
8.37%
* Growth figures are affected by the currency rate changes.
Company News (Not included in report)
Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

Request a demonstration of the EMIS service

To view more information, Request a demonstration of the EMIS service